Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Injectable MPL allergy vaccine - Allergy Therapeutics

Next Previous
Drug Profile

Injectable MPL allergy vaccine - Allergy Therapeutics

Alternative Names: Birch MATA MPL; Birch pollen allergen extract; Birch pollen modified allergen tyrosine-absorbed; Grass MATA MPL; Grass pollen modified allergen tyrosine-adsorbed; Pollinex Quattro; Pollinex Quattro Grass; Pollinex Quattro Tree; Pollinex Quattro® Birch; PQ Birch; PQ Grass; Tree MATA MPL

Latest Information Update: 09 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Grass pollen hypersensitivity; Tree pollen hypersensitivity
  • Preregistration Allergic rhinoconjunctivitis
  • Phase II/III Seasonal allergic rhinitis

Most Recent Events

  • 01 Mar 2025 Allergy Therapeutics plans a phase III trial for Allergic rhinoconjunctivitis in Austria, Germany, Poland (Injection)(CTIS2023-507427-28-00)
  • 28 Feb 2025 Efficacy data from a phase III trial in Allergic rhinoconjunctivitis presented at the 2025 Annual Meeting of the American Academy of Allergy, Asthma and Immunology/World Allergy Organization Joint Congress (AAAAI-WAO-2025)
  • 28 Feb 2025 Efficacy data from a phase III trial in Allergic rhinoconjunctivitis presented at the 2025 Annual Meeting of the American Academy of Allergy, Asthma and Immunology/World Allergy Organization Joint Congress (AAAAI-WAO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top